INTRODUCTION
The enterohepatic circulation of bile acids is the result of the coordinated action of membrane-transport and bile-acid-binding proteins [1] [2] [3] [4] . Bile acids are synthesized in the liver from cholesterol and are secreted into bile. In the intestine bile acids assist in absorbing cholesterol, fat and fat-soluble vitamins. Extensive intestinal absorption of bile salts results in less than 5 % faecal loss of the daily bile-acid pool. Absorbed bile acids are returned to the liver, where they are taken up into hepatocytes. In recent years many of the transport systems involved in the enterohepatic circulation of bile acids have been characterized at the molecular level. At the sinusoidal membrane of hepatocytes, bile acids are mainly taken up from blood by the Na + \ taurocholate co-transporting polypeptide (Ntcp) [5, 6] . Secretion of bile acids into bile at the canalicular membrane of hepatocytes is mainly mediated by the canalicular bile salt export pump (BSEP), also known as ' Sister of P-glycoprotein ', a membrane protein belonging to the ATP-binding-cassette (' ABC ') family of transporters [7, 8] . Absorption of bile salts into enterocytes in the intestine occurs mainly in the distal ileum through the action of the apically located ileal Na + -dependent bile-acid transporter (ASBT) [9] [10] [11] [12] . In the enterocytes, bile acids are transported across the basolateral membrane into the portal vein. The transporter for this last step has not been identified yet, and remains one of the ' missing links ' in the transport of bile acids in the enterohepatic circulation.
Recently, two distinct transport proteins have been implicated as possible candidates for the basolateral transport system of enterocytes. The first, described by Lazaridis et al. [13] is a truncated form of Asbt (t-Asbt) which is the result of differential splicing. The t-Asbt localizes to the basolateral membrane of ileocytes and cholangiocytes. When expressed in Xenopus oocytes it mediates Na + -independent taurocholate efflux. A second candidate is the multidrug resistant protein 3 (MRP3) [14] [15] [16] . MRP3 localizes to the basolateral membranes of polarized cells, is expressed in human [17] and in mouse intestine (N. Zelcer, A. Kuil and P. Borst, unpublished work) and is highly upregulated in the livers of rats made cholestatic by bile-duct ligation, or in cholestatic human liver [15, [18] [19] [20] [21] [22] . These findings suggest that MRP3 plays a role in the reabsorbtion of bile salts from the intestine and in the removal of toxic organic anions from the liver under cholestatic conditions. Initial studies with rat Mrp3 verified this and demonstrated that rat Mrp3 transports not only organic anions with a preference towards the sulphated and glucuronidated ones [23] , but also the bile acids taurocholate, glycocholate, taurochenodeoxycholate 3-sulphate and taurolithocholate 3-sulphate, laying a possible link between Mrp3 and the enterohepatic circulation of bile acids [24] . Recently, human MRP3 has been demonstrated to transport glycocholate, but not taurocholate [25] . Additionally, whereas rat Mrp3 has a high affinity for taurocholate and glycocholate, human MRP3 seems to have a low affinity for the latter.
In the present study we further characterize bile-acid transport by human MRP3 in membrane vesicles from Spodoptera frugiperda (Sf 9 ; fall armyworm) insect cells that were infected with a recombinant MRP3 cDNA containing baculovirus [26] . To study the possibility that Asbt and MRP3 co-operate under physiological conditions in vectorial transport of bile acids across enterocytes and cholangiocytes, we also generated a fibroblast cell line that stably expresses either one or both transporters. 
EXPERIMENTAL

Cell lines
The fibroblast cell line used in the present study, the generation of clones that stably overproduce MRP3 and growth conditions were described previously [26] . Cell lines were regularly checked for the absence of Mycoplasma infection.
Construction of a cell line expressing MRP3 and Asbt
A cDNA insert encoding mouse Asbt-His ' (His ' is a hexahistidine tag) [27] was excised from pZmISBT using EcoRI, blunted, and cloned into the EcoRV site of the retroviral pBabeBLEO vector [28] . The correctness of the resulting pBabeBLEO-Asbt-His ' vector was verified by digestion analysis. The pBabeBLEO-AsbtHis ' vector was transfected into the amphotropic retroviral packaging cell line Phoenix [28] . The virus particles produced were used to transduce cells that overproduce MRP3 (M3 cells) and the control clone V1, which does not. As controls, the same lines were transduced with virus particles that contained no Asbt-His ' cDNA insert. After 48 h, the cells were split and stable clones were selected with bleomycin (25 µg\ml). Resistant clones were expanded and analysed for Asbt-His ' expression using a mouse monoclonal antibody directed against the His ' tag (Qiagen, Leusden, The Netherlands) according to the manufacturer's protocol. MRP3 was detected using the monoclonal antibody M $ II-9 (1 : 250) as previously described [15] . Both primary antibodies were followed by a rabbit anti-mouse IgGhorseradish peroxidase conjugate (1 : 1000) and visualized by enhanced chemiluminescence (ECL2, Amersham, Little Chalfont, U.K.). For detection of murine Bsep and Mrp3 we used the monoclonal antibody C219 and a rabbit serum directed against Mrp3 respectively (N. Zelcer, I. Bot and P. Borst, unpublished work). The clones selected for study did not differ in morphology, size or volume (results not shown).
Bile-acid accumulation assays
Short-term bile-acid-accumulation assays were performed as described by Saeki et al. [27] . Briefly, 1i10' cells\well were plated 1 day prior to assay. On the following day, cells were washed twice with 37 mC pre-warmed wash buffer (250 mM mannitol\ 20 mM Tris\HCl, pH 7.4). Subsequently, cells were incubated with 37 mC pre-warmed uptake buffer [100 mM NaCl (or choline chloride)\3 mM KH # PO % \10 mM Tris\HCl (pH 7.4)\glucose (4.5 g\litre)] containing ["%C]glycocholate or [$H]taurocholate at the indicated concentrations. Similar results were obtained when the buffer system reported by Sun et al. [11] was used (results not shown). Unless otherwise indicated, uptake into the cells was measured after 5 min. Assays were terminated by washing the cells twice with cold wash buffer containing 500 µM taurocholate or glycocholate. The cell monolayer was lysed with 1 ml of 0.2 M NaOH at 37 mC for at least 1 h, and aliquots were taken to determine cellular protein and cell-associated radioactivity using liquid-scintillation counting in a Packard 1900CA counter (Packard, Meriden, CT, U.S.A.). To study the inhibition of Asbt-mediated bile-acid uptake, inhibitors at the indicated concentrations were added to the uptake buffer.
Bile-acid efflux assays
Efflux assays were performed as described above for uptake assays, with the exception that, following the uptake phase, cells were washed twice with cold wash buffer containing 500 µM non-radioactive taurocholate or glycocholate and incubated with 1 ml of efflux buffer [100 mM choline chloride\3 mM KH # PO % \10 mM Tris\HCl (pH 7.4)\glucose (4.5 g\litre)]. At the indicated times, samples (100 µl) were taken and their radioactive content determined by liquid-scintillation counting. At the end of the assay, cells were processed as described above.
Preparation of membrane vesicles
Sf 9 cells were infected with MRP3-expressing baculovirus at a multiplicity of infection of 1. After incubation at 27 mC for 3 days, cells were harvested by centrifugation at 500 g for 5 min. The pellet was resuspended in ice-cold hypo-osmotic buffer (0.5 mM Na + phosphate\0.1 mM EDTA, pH 7.4) supplemented with protease inhibitors (2 mM PMSF, 5 µg\ml aprotinin, 5 µg\ ml leupeptin and 10 µM pepstatin) and incubated at 4 mC for 90 min. The suspension was centrifuged at 4 mC at 100 000 g for 40 min and the pellet was homogenized in ice-cold TS buffer (50 mM Tris\HCl\250 mM sucrose, pH 7.4) using a tight-fitting Dounce homogenizer. After centrifugation at 500 g at 4 mC for 10 min, the supernatant was centrifuged at 4 mC at 100 000 g for 40 min. The pellet was resuspended in TS buffer and passed 20 times through a 27-gauge needle. The vesicles were dispensed in aliquots, frozen in liquid nitrogen, and stored at k80 mC until use.
Vesicular-transport assays
The time-and concentration-dependent uptake of various substrates into MRP3-containing vesicles was studied following the rapid-filtration method previously described [26] . Briefly, membrane vesicles containing 20 µg of protein were incubated with the indicated concentration of substrate in 50 µl of TS buffer in the presence of 4 mM ATP or AMP, 10 mM MgCl # , 10 mM creatine phosphate and creatine kinase (100 µg\ml). At the indicated time, the reaction mixture was diluted in 1 ml of icecold TS buffer and immediately filtered through a pure-cellulose filter (0.45 µm pore size). The filter was washed twice with 3 ml of ice-cold TS buffer and the radioactivity retained on the filter measured by liquid scintillation.
Statistics
Differences were tested with a two-tailed, non-paired Student's t test. A P value of 0.05 was considered significant.
RESULTS
Bile-acid vesicular-uptake studies
To study transport of bile acids by MRP3 we used vesiculartransport assays with membrane vesicles generated from Sf 9 cells infected with a recombinant baculovirus encoding MRP3. These vesicle membranes contain higher levels of MRP3 protein than 
Figure 2 Lineweaver-Burk plot of MRP3-mediated E 2 17βG transport and its inhibition by taurolithocholic acid sulphate
Rates of ATP-dependent transport of [ 3 H]E 2 17βG by MRP3 were determined in membrane vesicles from Sf 9 cells infected with a MRP3 baculovirus at four different concentrations in the absence (triangles) or presence of 20 µM taurolithocholic acid sulphate (squares) at 37 mC for 2 min. The ATP-dependent transport of E 2 17βG in membrane vesicles from Sf 9 cells infected with a wild-type baculovirus were subtracted from those obtained in membrane vesicles with MRP3, and each point represents the meanpS.D. from triplicate determinations.
we have been able to obtain in transfected mammalian cells and can be used to study organic-anion transport by MRP3 [26] . With these vesicles, we found a time-and ATP-dependent uptake of both glycocholate and taurocholate into MRP3 vesicles that is higher than with vesicles generated from Sf 9 cells infected with wild-type baculovirus (Figure 1 ). However, as is evident from Figure 1 , Sf 9 cells contain a background transporter for both of these bile acids which does not require ATP. Our attempts to saturate this endogenous transporter by increasing the concentration of bile salt used in the assay did not decrease the background. The endogenous bile-salt transporter precluded the determination of reliable kinetic parameters for bile-salt transport by MRP3 and we therefore took an indirect approach. We previously showed that, in the same vesicular system, etoposide glucuronide, the major metabolite of the anticancer drug etoposide formed in i o, is a good substrate of MRP3 [26] . We therefore used the inhibition of MRP3-mediated etoposide glucuronide transport to study the interaction of MRP3 with bile acids and other organic anions (Table 1) . MRP3-mediated transport of etoposide glucuronide was inhibited by several bile acids in a dose-dependent manner. Sulphated bile acids showed strong inhibition of MRP3-mediated transport at low concentrations (IC &! $ 10 µM), as has been found previously for rat Mrp3 [24] . Taurolithocholic acid sulphate inhibited the transport of E # 17βG in a competitive fashion with a K i of 11 µM (Figure 2) . MK571 also inhibited MRP3, although at much higher concentrations than those required for MRP1 (Table 1) .
Since sulphated bile salts are high-affinity competitive inhibitors of MRP3, we tested the effect of 4-methylumbelliferone sulphate (4-MUS), another sulphated compound on MRP3-mediated transport. Previously, Hirohashi et al. [23] demonstrated that 4-MUS stimulated the ATP-dependent transport of E # 17βG by rat Mrp3. We find a similar effect with human MRP3. Transport of E # 17βG by MRP3 was stimulated in a dose-dependent manner by 4-MUS (Figure 3) . This stimulation appears to be specific for the substrate E # 17βG, as we did not observe it with etoposide glucuronide or leukotriene C % as substrate (results not shown). It is also specific for the sulphate conjugate of 4-methylumbelliferone, as the glucuronide only 
Figure 4 Immunoblot analysis of Asbt and MRP3 in selected clones
A 40 µg portion of total cell protein was size-fractionated on an 1 % (w/v)-SDS/7.5 % (w/v)-polyacrylamide gel and Asbt-His 6 expression in selected clones was studied by Western-blot analysis using a monoclonal antibody against the His 6 tag (A). An Asbt-His 6 band is present in cells transduced with the Asbt cDNA construct (I clones). A non-specific band is seen in all the clones [marked by a star (N)]. Underlined clones were used in subsequent studies. MRP3 was detected (B) by using monoclonal antibody M 3 II-9 [15] .
inhibited MRP3-mediated transport (Figure 3 ). The stimulation is specific for MRP3, as we did not observe it with MRP1, tested under identical conditions in Sf 9 vesicles (results not shown). We did see a stimulation of background leukotriene C % transport by 4-MUS in Sf 9 vesicles not containing MRP3. This was not seen with E # 17βG as substrate (results not shown). Finally, despite the capacity of 4-MUS to stimulate E # 17βG transport by MRP3, it did not stimulate MRP3-mediated glycocholate transport at a concentration of up to 166 µM (results not shown). 
Generation of stable cell lines co-expressing Asbt and MRP3
The problems encountered with MRP3-mediated vesicular bileacid transport led us to develop a complementary cellular-based approach. To recapitulate the physiological situation where Asbt and MRP3 localize to opposing membranes of polarized cells, we attempted to generate Madin-Darby canine kidney-II (MDCK-II) cells that express both transporters. Although we managed to obtain clones that express both transporters in the correct membrane, we could not study the contribution of MRP3 to the basolateral transport of bile acids owing to the high activity of an uncharacterized endogenous basolateral bile-acid transporter.
As an alternative, we transduced fibroblast cell lines that overproduce MRP3 with virus generated from the pBabeBLEO\Asbt-His ' retroviral construct. These fibroblasts were generated from the kidneys of mice that have a homozygous disruption of Mdr1a, Mdr1b and Mrp1, and MRP3 expression in these cells results in resistance to the anticancer drug etoposide [26] . We screened clones that were resistant to 25 µM bleomycin by protein blot analysis ( Figures 4A and 4B) and by a functional assay in which we determined the Na + -dependency of [$H]taurocholate and ["%C]glycocholate uptake (results not shown). In all the clones transduced with the Asbt-His ' cDNA construct (I clones), a specific band was detected with an approximate size of $ 45 kDa, as has been reported by others [29] . In these clones, uptake of bile acids was completely dependent on the presence of Na + , since replacement of Na + by choline resulted in bile-acid uptake levels similar to those found in control clones transduced with the empty pBabeBLEO virus (results not shown). MRP3 in all the M3 clones is detected as a double band ( Figure 4B ), presumably resulting from differential glycosylation. We have previously shown in other cells that treatment with tunicamycin, which blocks N-glycosylation, results in the two MRP3 bands shifting to one band which runs with higher mobility [15] . A subset of the clones having similar bile-acid uptake was selected for further study.
Bile-acid uptake and efflux assays with Asbt/MRP3 cells
We loaded cells for 5 min with 0.25 µM [$H]taurocholate or either 7 µM [$H]taurocholate or 7 µM ["%C]glycocholate and monitored the subsequent efflux. Cellular uptake in the clones studied was similar (Table 2 ) and, once cells were washed and Na + was replaced by choline, a higher fraction of the accumulated radioactivity was recovered in the efflux media of MRP3-containing clones. This indicates that MRP3 transports both Characterization of bile-acid transport by multidrug resistance protein 3
Figure 5 Increased efflux of glycocholate and taurocholate from MRP3-expressing cells
Selected clones were incubated for 5 min at 37 mC with 7 µM [ 14 C]glycocholate (A) or 0.25 µM [ 3 H]taurocholate (B) in uptake buffer, washed, and allowed to efflux into Na + -free buffer. The fraction of the intracellular radioactivity that was retrieved in the efflux medium is plotted. The 100 % values are presented in Table 2 . Values for clones I9 (), M3-I23 (>) and M3-I18 (#) represent the mean valuepS.D. for experiments done in triplicate (n l 4).
glycocholate and taurocholate ( Figure 5 ), a finding that supports our results with the vesicular transport system. The efflux rates of glycocholate and taurocholate correlate well with the level of MRP3 expression in the clones studied (Figure 4) . Clone M3-I18, which has the highest expression of MRP3, has also the highest rate of bile-acid efflux, followed by M3-I23. A third MRP3 clone, M3-I7, in which MRP3 expression is lower than that of M3-I23 ( Figure 4 ) had taurocholate-efflux rates which were intermediate between those of clone M3-I23 and the control clone I9, despite having a lower accumulation of taurocholate (results not shown). Loading the cells with 7 µM taurocholate instead of 0.25 µM leads to a proportional increase in the intracellular taurocholate concentration (Table 2) . Under these conditions, the efflux mediated by MRP3 is also proportionally increased, indicating that the capacity of taurocholate transport by MRP3 in these cells is high (results not shown). In these assays we consistently recovered 95-100 % of the radioactivity. Interestingly, the control clone I9, which has no MRP3, nevertheless showed a low level of bile-acid efflux ( Figure 5) . A similar result was obtained with an additional control clone, namely I7 (results not shown). By protein blot analysis we could not detect the presence of mouse Mrp3 or Bsep. When 25 µM taurocholate was included in the efflux buffer, the basal bile-salt efflux from the control clone was further stimulated by 20 % at 10 min. This suggests that our cells contain an organic-anion-transport-protein (OATP)-like transporter that is able to exchange the intracellular [$H]taurocholate for extracellular taurocholate [30] . Presumably, the MRP3 clones contain this system as well.
To further verify that MRP3 is responsible for the transport of bile acids in our clones, we attempted to inhibit it. Since no specific high-affinity inhibitors are known for MRP3, we tested a panel of inhibitors of organic-anion transport that have been shown to inhibit MRP3 in intact cells and membrane vesicles (Table 3 ). The tested inhibitors are commonly used drugs and are often used to inhibit MRPs. Unexpectedly, however, all the inhibitors tested inhibited the Na + -dependent uptake of bile acids by Asbt at concentrations lower than those required to inhibit MRP3. Because of this complication, we could only add the inhibitor during the efflux phase of our experiments. Under these conditions 2 mM sulphinpyrazone substantially inhibited MRP3-mediated glycocholate transport. Transport of glycocholate at 5 min by clones M3-I18 and M3-I23 was reduced to 46p16 (meanpS.D.) and 56p16 % of transport in the presence of inhibitor, whereas transport by the control clone V1 was only slightly reduced to 81p10 % (n l 3).
Time-and concentration-dependent uptake of glycocholate by cells expressing Asbt with and without MRP3
Glycocholate was chosen instead of taurocholate for these studies since MRP3 has a higher affinity for this bile salt ( Figure 1 and Table 1 ) and its efflux by MRP3 is higher ( Figure 5 ). The accumulation of ["%C]glycocholate with time is initially similar in clones V1-I9 and M3-I18. However, after 10 min, the accumulation in clone M3-I18, which contains MRP3 along with Asbt, is reduced compared with the control V1-I9 clone ( Figure 6A) . Presumably, at that time, MRP3-mediated glycocholate efflux can partially counter the influx that is mediated by Asbt. However, the rate of influx remains higher than that of the efflux process, since the cells continue to accumulate ["%C]glycocholate with time. Therefore, to get a rough estimate for the rate of high rate of transport we obtain in the transfected clones is the result of the high, and probably non-physiological, levels of MRP3 in these cells. However, as Figure 7 clearly demonstrates, the level of MRP3 in clone M3-I18 is, when assessed by densitometry, only 10-fold higher than that found in normal human liver.
DISCUSSION
In recent years many of the major transporters involved in the enterohepatic circulation of bile acids have been cloned, biochemically characterized and their altered expression in the cholestatic state described [4, 31] . Moreover, their importance for the enterohepatic circulation has been further illustrated in knockout mice [32, 33] and in the TR − \EHBR (Transport mutant\Eisai hyperbilirubinaemic rat) naturally occurring Mrp2-deficient rats [34] . Despite these advances, the molecular identity of the basolateral bile-acid transporter of enterocytes and cholangiocytes remains elusive. Two transporters have been recently suggested to fulfill this task, namely t-Asbt and MRP3. Differential splicing of Asbt results in t-Asbt, a transporter that localizes to the basolateral membranes of enterocytes and
Figure 7 Immunoblot comparison of MRP3 levels in normal human liver and clone M3-I18
A 50 µg portion of total cell protein from normal human liver or the indicated amounts from clone M3-I18 were size-fractionated on an 1 %-SDS/7.5 %-polyacrylamide gel and MRP3 expression in the samples was studied by Western-blot analysis using the monoclonal antibody M 3 II-9 [15] .
cholangiocytes. When expressed in Xenopus oocytes, t-Asbt mediates Na + -independent efflux of taurocholate [13] . Alternatively, Mrp3 might play a role in bile-acid transport. MRP3 is highly induced in cholestatic livers of humans and rats, suggesting that this transporter is important for the removal of toxic anions from the liver [15, 18, 19, 21] and direct transport of bile acids by rat Mrp3 [24] , and human MRP3 was observed in vesicular transport assays [25] . However, a large discrepancy was found between the two MRP3 orthologues. Whereas rat Mrp3 transports taurocholate with relatively high affinity (K m $ 16 µM), human MRP3 does not [24, 25] . Additionally, transport of sulphated bile acids, increased in cholestasis, has not been studied for MRP3. We initially studied MRP3-mediated bile-acid transport in vesicular transport assays. Using this system we could demonstrate a clear time-and ATP-dependent transport of both glycocholate and taurocholate, as has been found for rat Mrp3 (Figure 1 ). However, despite the high content of MRP3 in these membranes, the determination of the kinetic parameters for this transport was hampered by the presence of a substantial non-ATP-dependent bile-acid-transport activity in the control membranes. This background transport activity posed no problem when Bsep-mediated taurocholate transport was studied in Sf 9-derived membranes. Presumably this is due to the high affinity of Bsep for taurocholate (K m $ 5-7 µM) [7, 35] . Accordingly, this would suggest that the affinity of MRP3 for taurocholate and glycocholate is low. Support for this notion comes from our inhibition data (Table 1) , where relatively high concentrations of these bile acids are required to inhibit the MRP3-mediated etoposide glucuronide transport. The apparent IC &! for glycocholate is $ 250 µM, a value that is in good agreement with the published K m of MRP3 for this compound [25] . Taurocholate at a concentration of up to 500 µM could not inhibit 50 % of the MRP3-mediated transport, indicating that the affinity of MRP3 for this bile acid is even lower.
MRP3 expression is highly induced under conditions of impaired bile flow or under conditions where MRP2 expression is diminished, for example as in Dubin-Johnson-syndrome patients or in their animal counterparts, TR − \EHBR rats [15, [18] [19] [20] [21] . Additionally, in itro exposure of enterocytes to 100 µM chenodeoxycholic acid increases MRP3 RNA transcript levels 3-fold, indicating that its transcription is sensitive to bileacid levels [36] . Taken together, these observations suggest that MRP3 may compensate for the lack of MRP2 transport of organic anions and\or function as a bile-acid transporter when their levels are elevated. With this in mind, it is noteworthy that MRP3-mediated transport is competitively inhibited by low concentrations of sulphated bile acids (Table 1 and Figure 2 ), which are made in increased amounts during cholestasis [37] . This indicates that sulphated bile acids are high-affinity substrates of human MRP3, as has been demonstrated for the rat isoform [24] . Since sulphated bile acids are also high-affinity substrates of rat Mrp2 [35] , the high up-regulation of Mrp3 in the absence of functional Mrp2, as is seen in EHBR rats, might serve to remove these metabolites from the liver. We expect the induction of MRP3 in Dubin-Johnson patients to serve a similar purpose. MRP3-mediated transport is also inhibited by taurochenodeoxycholate (Table 1, IC &! $ 100 µM), the preferred substrate of Bsep [7] . The up-regulation of MRP3 may provide an escape route for this bile acid in some progressive-familialintrahepatic-cholestasis patients or in bile-duct-ligated rats in which bile efflux by Bsep is not diminished [38] .
MRP3 and Asbt localize to opposite membranes in polarized cells [11, 15, 29] . Accordingly, a simple model would suggest that bile acids taken up at the apical membrane by Asbt are transported across the basolateral membrane by MRP3. Optimally, polarized cells expressing both transporters would serve to test this hypothesis, as recently demonstrated for OATP8 (SLC21A8) and MRP2 [39] . However, it turned out that MDCK-II cells that stably express mouse or rat Asbt have a high capacity basolateral efflux system for taurocholate and glycocholate (N. Zelcer and P. Borst, unpublished work). The nature of the basolateral transporter of bile acids in the MDCK-II cells has not been further studied. As an alternative to the MDCK-II cells, we used a fibroblast cell line that expresses both MRP3 and Asbt (Figure 4 ). Although these cells are not polarized, they have previously proved to be suitable for studying transport of MRP3 substrates [26] . Clones that express MRP3 along with Asbt show a substantial increase in glycocholate and taurocholate efflux compared with the control clone ( Figure 5 ), in agreement with our inhibition results ( Table 1) . The rates of efflux from these cells correlate well with the levels of MRP3 (Figure 4) . Furthermore, cells that express Asbt accumulate glycocholate in a time-dependent manner ( Figure 6 ). If the cells additionally express MRP3, the accumulation of glycocholate slows down at a higher intracellular concentration. Assuming a cell volume of 1i10 −"& m$, the effect of MRP3 becomes apparent when intracellular concentrations of glycocholate reach about 400 µM, again indicating that the affinity of MRP3 for this bile acid is low. Yet, despite the low affinity, the capacity of transport is high, as it can partially counteract the influx of glycocholate by Asbt, which has a high V max (Figure 6 ). Low affinity coupled to a high transport rate of glycocholate by MRP3 was also found by Zeng et al. in membrane vesicles from HEK293 cells overexpressing MRP3 [25] . In accordance with this, when we increased the taurocholate concentration used for loading the cells from 0.25 µM to 7 µM, the initial efflux rate increased as well. We realize that the transfected cell system used by us to study bilesalt transport is rather unphysiological, not only because it is not polarized, but also because it lacks the bile-acid-binding protein present in the ileal mucosa which facilitates intracellular transport and protects against the detergent effects of bile salts [40] . Moreover, the level of MRP3 in our transfected cells is substantially higher than in normal human liver (Figure 7) . However, it has been shown that MRP3 levels can go up at least 10-fold in rats or human liver under pathological conditions [19] [20] [21] , bringing the MRP3 concentration into the same range as in our transfected cells. Taken together, our results suggest that MRP3 can contribute to bile-salt efflux, at least in liver cells under some pathological conditions, and are compatible with the notion that MRP3 transports bile salts with low affinity and high capacity in i o. Interestingly, control clones, which only express Asbt, also had low levels of bile-acid efflux ( Figure 5 ), as has been seen in many cell types. In fact, even cells which are not normally exposed to bile acids, such as Xenopus oocytes, contain an unidentified bile-acid transporter [41] . Low-level expression of endogenous t-Asbt might explain the basal efflux we see in the control cells, but expression of t-Asbt seems to be restricted to specific cells in the ileum, liver and kidney [9, 10, 29] , and we do not expect our fibroblast cell line to express it. More likely, members of the rodent Oatp family of transporters might be expressed in our fibroblast cell line, and this is supported by the trans-stimulation of efflux by taurocholate that we find in the control clones, a characteristic of Oatps observed by others [30, 42] and studied in the basolateral membrane of isolated cholangiocytes [43] and ileocytes [44] .
The question can be raised as to whether the low affinity for bile acids that we find for MRP3 could be due to the requirement of an additional anion for efficient co-transport, as has been shown for several MRP1 substrates. MRP1 transport of oestrone 3-sulphate is GSH-dependent [45] , and etoposide glucuronide transport by MRP1 is stimulated by the presence of GSH [46] . Similarly, we find that E # 17βG transport by MRP3 is strongly stimulated by the presence of 4-MUS (Figure 3 ), raising the possibility that optimal transport of bile acids by MRP3 requires a co-substrate. No stimulation of glycocholate transport by 4-MUS was seen, however. We also consider a requirement of a co-substrate for optimal bile-acid transport by MRP3 unlikely, as we obtain similar results for bile-acid transport by MRP3 in cellular-transport and vesicular-uptake assays. Nevertheless, we cannot rule out the possibility that our cellular system lacks an organic anion present in the cells in which MRP3 is normally active that can stimulate the transport of bile acids.
Our results indicate that MRP3 transports glycocholate and taurocholate with a low affinity and high capacity. This indicates that MRP3 does not substantially contribute to bile-acid transport under physiological conditions and is therefore not the main basolateral transporter of bile acids in ileocytes and cholangiocytes. During cholestasis, however, plasma concentrations of bile acids may reach levels of up to 500 µM [37] . Under these conditions MRP3 is highly induced and, as shown here, could play a substantial role in protecting cells against the toxic buildup of intracellular bile salts. Sulphation of bile acids and their urinary excretion is increased in the cholestatic state as well [37] . MRP3, like its rat orthologue, has a high affinity for sulphated bile acids and it is therefore conceivable that, in cholestasis, MRP3 plays a major role in transporting sulphated bile acids into the circulation from which they can be excreted into urine.
